Effect of menopausal hormone therapy on COVID-19 severe outcomes in women – A population-based study of the US National COVID Cohort Collaborative (N3C) data. (April 2023)

• Record Type: Journal Article
• Authors: Yoshida, Yilin; Chu, San; Zu, Yuanhao; Fox, Sarah; Mauvais-Jarvis, Franck
• Is Part Of: Maturitas. Volume 170(2023)
• Page Start: 39
• Page End: 41
• Publication Date: 2023-04
• Subjects: Menopausal hormone therapy -- COVID-19 -- Mortality -- Hospitalization; Climacteric -- Periodicals; Menopause -- Periodicals; Climacteric -- Periodicals; Geriatrics -- Periodicals; Menopause -- Periodicals; Middle Aged -- Periodicals; Climatère -- Périodiques; Ménopause -- Périodiques; Climacterium; Climacteric; Menopause; Electronic journals; Periodicals; 612.66
• DOI: 10.1016/j.maturitas.2022.10.005
• Languages: English
• ISSNs: 0378-5122

Abstract

Highlights: Menopausal hormone therapy may lessen the severity of COVID-19. The use of menopausal hormone therapy was associated with a marginally lower risk of COVID-19 mortality in inpatients. The use of menopausal hormone therapy was also associated with a significantly reduced risk of prolonged hospital stay. Abstract: Whether menopausal hormone therapy (MHT) lessens the severity of COVID-19 among women is unclear. Leveraging a U.S. national COVID-19 cohort and a cross-sectional analysis, we found MHT use was marginally associated with a lower risk of mortality (odds ratio [OR] 0.73, 95 % CI 0.53–1.01) and significantly associated with a lower risk of prolonged hospital stay (0.7, 0.49–0.99) among inpatient women. When stratifying by MHT type, estrogen-only and estrogen-plus-progestin therapies had a more prominent protective effect than progestin-only therapy, although this difference did not achieve statistical significance. Women with COVID-19 can continue to use MHT. Clinical trials are needed to evaluate MHT's therapeutic effect on COVID-19, especially in terms of severity.